BioScrip (BIOS) : Traders are bullish on BioScrip (BIOS) as it has outperformed the S&P 500 by a wide margin of 10.06% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.59%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.76% in the last 1 week, and is up 9.47% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 5.34% and the 50-Day Moving Average is 6.7%.The 200 Day SMA reached 23.72%
BioScrip (NASDAQ:BIOS): The stock was completely flat for the day, closing at $2.89 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $2.89, the stock touched an intraday high of $2.96 and a low of $2.83. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $2.89. The total trading volume on Friday was 689,993.
BioScrip (BIOS) : The highest short term price target forecast on BioScrip (BIOS) is $5 and the lowest target price is $3. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $3.92 with a standard deviation of $1.13.
BioScrip, Inc. is engaged in providing infusion and home care management solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payers and pharmaceutical manufacturers to provide patients access to post-acute care services. Its segments include Infusion Services and Pharmacy Benefit Management (PBM) Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Its PBM Services segment consists of integrated PBM services, which primarily consists of discount card programs that provide alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. It provides products, services and condition-specific clinical management programs for health conditions, such as gastrointestinal abnormalities, infectious diseases, and others.